Publications using blood samples or tissue from the BIOPAC cohort​

• 56 Willumsen N, Henriksen K, Bager C, Hansen Selnø AT, Mohamed KE, Leeming DJ, Skarsfeldt MA, Nissen NI, Pedersen RS, Thorlacius-Ussing J, Dziegiel MH, Tang ME, Jørgensen LN, Diab HMH, Chen IM, Johansen JS, Vitorino P, Sarkar A, Bradshaw A, Karsdal MA. BIGH3 is a mediator of TGFβ-induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target. Sci Rep 2025; 15: 40867. PMID:41258233 (IF 3.9)
  
• 55 Stubbe B, Stoico MP, Terp SK, Madsen PH, Lundbye-Christensen S, Hansen CP, Poulsen LØ, Rasmussen LS, Yilmaz MN, Jensen LH, Hansen TF, Pfeiffer P, Larsen AC, Krarup HB, Pedersen IS, Hasselby JP, Johansen AZ, Chen IM, Johansen JS, Thorlacius-Ussing O, Henriksen SD. Promoter hypermethylation of SFRPQ is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Front Oncol 2025;15:1568386. PMID:40492125 (IF 3.3)
  
• 54 Steiniche MM, Lindgaard SC, Chen IM, Johansen JS, Andersen RF, Hansen TF, Jensen LH, Rasmussen LS, Johansen MW, Ladekarl M, Jakobsen A, Spindler KL G. The prognostic impact of ctDNA kinetics in metastatic pancreatic cancer using ctDNA response evaluation criteria in solid tumors (ctDNA-RECIST). Clin Cancer Res 2025;31:4720-29. PMID:40970773 (IF 10.2)
  
• 53 Pedersen RS, Hettich A, Thorlacius-Ussing J, Langholm LL, Crespo-Bravo M, Chen IM, Hansen CP, Johansen JS, Diab HMH, Jorgensen LN, Karsdal M, Willumsen N. Proteolytic degradation of Beta-Ig H3 (βigH3/TGFB1) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer 2025;25:905. PMIS:40394523 (IF 3.4).
  
• 52 Kollbeck S, Hansen CP, Bonde MT, Dencker EE, Burgdorf SK, Storkholm JH, Krohn PS, Johansen AZ, Millarch AS, Hillingsø JG, Christensen JF, Johansen JS, Sillesen M. Grim age, Grim prognosis: Epigenetic aging predicts pancreatic surgery risk. Ann Surg 2025, online ahead of print. PMID:40810414 (IF 6.4)
  
• 51 Hruban C, Bruhm DC, Chen IM, Koul S, Annapragada AV, Vulpescu NA, Short S, Theile S, Boyapati K, Alipanahi B, Skidmore ZL, Leal A, Christiano S, Adleff V, Johansen JS, Scharpf RB, Foda ZH, Phallen J, Velculescu VE. Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. Sci Adv 2025;11:eads5002. PMID:40397745 (IF 11.7)
  
• 50 Eefsen RL, Christensen IJ, Johansen AZ, Chen IM, Calatayud D, Pfeiffer P, Andersen F, Johansen JS, Højer-Hansen G. Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer. Eur J Cancer 2025;231;116095. PMID:41205255 (IF 7.1)
  
• 49 Chen IM, Theile S, Madsen K, Johansen JS, Lorentzen T, Toxværd A, Høgdall E, Svane IM, Nielsen D. A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE). Immunooncol Technol 2025;26:101054. PMID:40475164 (IF 4.82)  ​
• 48 Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Crawford A, Neelon B, Guttridge DC, Ostrowski M, Zimmers TA, Nielsen D. Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer (PACTO): survival and cachexia. J Clin Oncol 2025;43:2107-18. PMID:40354592 (IF 42.1)
  
• 47 Magni L, Yu H, Christensen NM, Poulsen MH, Frueh A, Deshar G, Johansen AZ, Johansen JS, Pless SA, Jørgensen NR, Novak I. Human P2X7 receptor variants Gly150Arg and Arg276His polymorphisms have differential effects on risk association and cellular functions in pancreatic cancer. Cancer Cell Int 2024;24:148. PMID: 38664691 (IF 6.435) 
  
• 46 Christensen TD, Maag E, Theile S, Madsen S, Lindgaard SC, Hasselby JP, Nielsen DL, Johansen JS, Chen IM. Circulating immune-related proteins associated with immune checkpoint inhibitor efficacy in patients with pancreatic ductal adenocarcinoma. ESMO open 2024;9:103489. PMID:38838501 (IF 7.1).​
• 45 Stuhr LK, Madsen K, Johansen AZ, Chen IM, Hansen CP, Jensen LH, Hansen TF, Kløve-Mogensen K, Nielsen KR, Johansen JS. Combining sCD163 with CA 19-9 increases the predictiveness of pancreatic ductal adenocarcinoma. Cancers 2023:15:897. PMID: 36765852 (IF 6.575).  
  
• 44 Stubbe BE, Larsen AC, Madsen PH, Krarup HB, Pedersen IS, Lundbye-Christen S, Hansen CP, Hasselby JP, Johansen AZ, Thorlacius-Ussing O, Johansen JS, Henriksen SD. Promotor hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma. Front Oncol 2023;13:1211292. PMID: 37333823 (IF 6.244).
• 43 Stubbe BE, Madsen PH, Larsen AC, Krarup HB, Pedersen IS, Hansen CP, Johansen JS, Henriksen SD, Thorlacius-Ussing O. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma. Pancreatology 2023; in press. PMID: 37230892.
• 42   Nissen NI, Johansen AZ, Chen IM, Jensen C, Madsen EA, Hansen CP, Thorlacius-Ussing J, Karsdal M, Johansen JS, Diab HMH, Jørgensen LN, Willumsen N. High serum levels of the C-propeptide of type V collagen (PRO-C5) are prognostic for overall survival in patients with pancreatic ductal adenocarcinoma. Front Mol Biosci 2023:10:1158058. PMID: 36968275. (IF 5.59).
• 41 Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, Bhambhvani H, Smith K, Johansen JS, Makawita S, Musher B, Mehta A, Hendifar A, Wainberg Z, Sohal D, Fountzilas C, Singhi A, Rajpurkar P, Collisson EA. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Cell Rep Med 2023;4:101013. PMID: 37044094. (IF 16.988).  
• 40 Lindgaard SC, Sztupinszki Z, Maag E, Hansen CP, Chen IM, Johansen AZ, Hasselby JP, Bojesen SE, Nielsen D, Johansen JS. Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Cancer Med 2023;12:3972-86. PMID: 36250429. (IF 4.711).
• 39 Hansen LB, Jakobsen SF, Zole E, Noer JB, Fang LT, Alizadeh S, Johansen JS, Mohiyuddin M, Regenberg B. Methods for the purification and detection of single nucleotide KRAS mutations on extrachromosomal circular DNA (eccDNA) in human plasma. Cancer Medicine 2023; in press. PMID (IF 4.711)
• 38   Christensen TD, Jensen C, Larsen O, Leerhøy B, Hansen CP, Madsen K, Høgdall D, Karsdal MA, Chen IM, Nielsen D, Johansen JS, Willumsen N. Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer. Int J Cancer 2023;152:1036-49. PMID: 36455598. (IF 7.316).
• 37 Christensen TD, Madsen K, Maag E, Larsen O, Jensen LH, Hansen CP, Markussen A, Høgdall DTS, Chen IM, Nielsen D, Johansen JS. Protein signatures and individual circulating proteins, including IL-6 and IL-15, associated with prognosis in patients with biliary cancer. Cancers 2023;15:1062. PMID: 36831406. (IF 6.575).
• 36 Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Eur J Cancer 2023;180:125-33. PMID: 36592507. (IF 10.002).
• 35 Thorlacius-Ussing J, Jensen C, Madsen EA, Nissen NI, Manon-Jensen T, Chen IM, Johansen JS, Diab HMH, Jørgensen LN, Karsdal MA, Willumsen N. Type XX collagen is elevated in circulation of patients with solid tumors. Int J Mol Sci 2022;23:4144. PMID: 35456962. (IF 6.208).
• 34   Theile S, Johansen JS, Nielsen DL, Jensen BV, Hansen CP, Hasselby JP, Eriksson SV, Chen IM. A randomized placebo-controlled phase 2 study of gemcitabine and capecitabine with or without T-ChOS as adjuvant therapy in patients with resected pancreatic cancer (CHIPAC). Pharmaceutics 2022;14:509. PMID: 35335885. (IF 6.525).
• 33  Pedersen RS, Nissen NI, Jensen C, Thorlacius-Ussing J, Manon-Jensen T, Olesen ML, Langholm LL, Diab HMH, Jorgensen LN, Hansen CP, Chen IM, Johansen JS, Karsdal MA, Willumsen N. Plasma Kallikrein-activated TGF-β is prognostic for poor overall survival in patients with pancreatic ductal adenocarcinoma and associates with increased fibrogenesis. Biomolecules 2022;12;1315. PMID: 36139154. (IF 6.064).
• 32  Nissen NI, Johansen AZ, Chen I, Johansen JS, Pedersen RS, Hansen CP, Karsdal MA, Willumsen N. Collagen biomarkers quantify fibroblast activity in vitro and predict survival in patients with pancreatic ductal adenocarcinoma. Cancers 2022;14:819. PMID: 35159087. (IF 6.575).
• 31   Lindgaard SC, Maag E, Sztupinszki Z, Chen IM, Johansen AZ, Jensen BV, Bojesen SE, Nielsen DL, Szallasi Z, Johansen JS. Circulating protein biomarkers for prognostic use in patients with advanced pancreatic ductal adenocarcinoma undergoing chemotherapy. Cancers 2022;14:3250. PMID:35805022. (IF 6.575).
• 30  Høgdall D, O’Rourke CJ, Larsen FO, Zarforoushan S, Christensen TD, Ghazal A, Boisen MK, Munoz-Garrido P, Johansen JS, Andersen JB. Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. J Hepatol 2022;77:1047. PMID: 35750139. (IF 30.083)
• 29 Harryvan TJ, Hawinkels LJAC, mini-tumor workgroup, Östman A, Ten Dijke P, Strell C, Hornsveld M. A novel pancreatic cancer mini-tumor model to study desmoplasia and myofibroblastic cancer-associated fibroblast differentiation. Gastro Hep Adv 2022;1:678. PMID: 35937541.
• 28  Christensen TD, Maag E, Larsen O, Feltoft CL, Nielsen KR, Jensen LH, Leerhøy B, Hansen CP, Chen IM, Nielsen DL, Johansen JS. Development and validation of circulating protein structures as diagnostic biomarkers for biliary tract cancer. JHEP Rep 2022;5:100648. PMID: 36699667. (IF 9.917).
• 27   Chen IM, Johansen JS, Theile S, Hjaltelin JX, Novitski SI, Brunak S, Hasselby JP, Willemoe GL, Lorentzen T, Madsen K, Jensen BV, Wilken EE, Geertsen P, Behrens C, Nolsoe C, Hermann KL, Svane IM, Nielsen D. Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J Clin Oncol 2022;40:3180. PMID: 35476508. (IF 44.544).
• 26 Rasmussen LS, Yilmaz MK, Falkmer UG, Poulsen LØ, Bøgsted M, Christensen HS, Bojesen SE, Jensen BV, Chen IM, Johansen AZ, Hansen Cp, Hassselby JP, Holländer N, Nielsen SE, Andersen F, Bjerregaard JK, Pfeiffer P, Johansen JS. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Eur J Cancer 2021;144:72-80. PMID 33341448. (IF 9.162). (IF 10.002).
• 25 Nissen N, Kehlet S, Johansen AZ, Chen I, Karsdal M, Johansen JS, Diab HMH, Jørgensen LN, Shu S, Manon-Jensen T, Yi H, Langholm L, Willumsen N. Noninvasive prognostic biomarker potential of quantifying the pro-peptides of type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma. Int J Cancer 2021;149:228-38. PMID: 33687786. (IF 7.316).
• 24 Lindgaard SC, Sztupinszki ZM, Maag E, Chen IM, Johansen AZ, Jensen BV, Bojesen SE, Nielsen DL, Hansen CP, Hasselby JP, Nielsen KR, Szallasi Z, Johansen JS. Circulating protein biomarkers for use in pancreatic ductal adenocarcinom identification. Clin Cancer Res 2021;27:2592-2603. PMID 33737308. (IF 12.531).
• 23 Kjaergaard AD, Chen IM, Johansen AZ, Nordestgaard BG, Bojesen SE, Johansen JS. Inflammatory biomarker score identifies patients with six-fold increased risk of one-year mortality after pancreatic cancer. Cancers 2021;13:4599. PMID 34572824. (IF 6.639).
• 22 Henriksen SD, Stubbe BE, Madsen PH, Johansen JS, Jensen BV, Hansen CP, Johansen MN, Pedersen IS, Krarup H, Thorlacius-Ussing O. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma – an external validation study. Pancreatology 2021;21:1081-91. PMID: 33994313. (IF 3.977)
• 21 Gentiluomo M, Corradi C, Vanella G, Johansen AZ, Strobel O, Szentesi A, Milanetto AC, Hegyi P, Kupcinskas J, Tavano F, Neoptolemos JP, Bozzato D, Hackert T, Pezzilli P, Johansen JS, Costello e, Mohelnikova-Duchonova B, van Eijck CHJ, Talar-Wojnarowska R, Hansen CP, Darvasi E, Chen IM, Cavestro GM, Soucek P, Piredda L, Vodicka P, Gazouli M, Arcidiacono PG, Canzian F, Campa D, Capurso G. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Sci Rep 2021;11:7570. PMID: 33828170. (IF 4.996).
• 20 Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of unresectability and prognosis in patients undergoing surgery on suspicion of pancreatic cancer using carbohydrate antigen 19-9, interleukin 6, and YKL-40. Pancreas 2020;49:53-61. PMID: 31856080. (IF 3.327).
• 19 Høgdall D, O’Rourke CH, Dehlendorff C, Larsen OF, Jensen LH, Johansen AZ, Dang H, Factor VM, Grunnet M, Mau-Sørensen M, Oliveira DVNP, Linnemann D, Boisen MK, Wang XW, Johansen JS, Andersen JB. Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers. Clin Cancer Res 2020;26:5655-5667. PMID: 32933994. (IF 13.801).
• 18 Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP, Hasselby JP, Bojesen SE, Pfeiffer P, Nielsen SE, Holländer NH, Yilmaz MK, Karsdal M, Johansen JS. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Int J Cancer 2020;146:2913-2922. PMID: 31642523. (IF 7.316).
• 17 Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P, Bjerregaard JK, Nielsen SE, Andersen F, Holländer NH, Yilmaz M, Rasmussen LS, Johansen JS. Prognostic value of combined detection of serum IL6, YKL-40, and C-reactive protein in patients with unresectable pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2020;29:176-184. PMID: 31685562. (IF 3.67). 
• 16 Bagni K, Chem IM, Johansen AZ, Dehlendorff C, Jensen BV, Hansen CP, Preus Hasselby J, Holländer NH, Nissen M, Bjerregaard JK, Pfeiffer P, Yilmaz MK, Rasmussen LS, Nielsen SE, Johansen JS. Prognostic impact of Charlson’s age-comorbidity index and other risk factors in patients with pancreatic cancer. Eur J Cancer Care 2020; 29: e13219. PMID:31908093. (IF 2.334).
• 15 Obazee O, Archibugi L, Andriulli A, Soucek P, Malecka-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, Cavestro GM, Milanetto AC, Di Leo M, Pasquali C, Hegyi P, Szentesi A, Radu CE, Gheorghe C, Theodoropoulos GE, Bergmann F, Brenner H, Vodickova L, Katzke V, Campa D, Strobel Om Kaiser J, Pezzilli R, Federici F, Mohelnikova-Duchonova B, Boggi U, Lemstrova R, Johansen JS, Bojesen SE, Chen I, Jensen BV, Capurso G, Pazienza V, Dervenis C, Sperti C, Mambrini A, Hackert T, Kaaks R, Basso D, Talar-Wojnarowska R, Maiello E, Izbicki JR, Cuk K, Saum KU, Cantore M, Kupcinskas J, Palmieri O, Delle Fave G, Landi S, Salvia R, Fogar P, Vashist YK, Scarpa A, Vodicka P, Tjaden C, Iskierka-Jazdzewska E, Canzian F. Germline BRCA2 K3326X and CHECK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Int J Cancer 2019;145:686-693. PMID: 30672594. (IF 5.229).
• 14 Christiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CHJ, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 2019;570:385-389. PMID: 31142840. (IF 42.778).
• 13 Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collinson EA. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma. JCO Precis Oncol 2018;2018. PMID: 30506016. (IF 2.951). 
• 12 Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol 2018;36:2887-2894. (IF 24.008).
• 11 Strell C, Norberg KJ, Mezheyeuski A, Schnittert J, Kuninty PR, Moro CF, Paulsson J, Schultz NA, Calatayud D, Löhr JM, Frings O, Verbeke CS, Heuchel RL, Prakash J, Johansen JS, Östman A. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Br J Cancer 2017;117:65-77. (IF 6.176)
• 10  Chen I, Raymond VM, Geis JA, Collison EA, Jensen BV, Hermann HK, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNAKRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic cancer. Oncotarget 2017;8:97769-97786. (IF 5.16).
• 9 Calatayud D, Dehlendorff C, Boisen MK, Hasselby JP, Schultz NA, Werner J, Immervoll H, Molven A, Hansen CP, Johansen JS. Tissue microRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res 2017;5:8.
• 8  Laklai H, Miroshnikova YA, Pickup MW, Collison EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Lacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 2016;22:497-505. (IF 28.439).
• 7 Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Int J Cancer 2016;139:2312-2324. (IF 5.531). 
• 6 Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O’Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 2015;6:7686. (IF 11.470).
• 5 Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392-404. (IF 29.978).
• 4  Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregård JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen K, Johansen JS. Diagnostic and prognostic impact of circulating YKL-40 and IL-6 in patients with pancreatic cancer. PLOS One 2013;8:e67059. (IF 4.351). 
• 3  Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wøjdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Modern Pathology 2012;25:1609-22. (IF 4.176). 
• 2  Schultz NA, Roslind A, Christensen IJ, Horn T, Pedersen LN, Kruhøffer M, Burcharth F, Wøjdemann M, Johansen JS. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 2012;41:759-66. (IF 2.386).
• 1  Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wøjdemann M, Johansen JS. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer – five microRNAs in a prognostic index. World J Surgery 2012;36:2699-707. (IF 2.362).